Cytosorbents Corp
Cytosorbents Corp develops blood purification and adsorption devices used in critical care, cardiac surgery, and other acute care settings. Its lead product, CytoSorb, is sold in many countries outside the U.S., while the company is also pursuing regulatory approvals for DrugSorb-ATR and other product candidates in North America.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaHemoadsorption cartridges used in critical care and cardiothoracic surgery to remove inflammatory mediators and selected substances from blood.
A product candidate designed to remove antithrombotic drugs around surgery to reduce bleeding risk.
Includes ECOS-300CY, PuriFi and related device offerings used with extracorporeal blood treatment systems.
VetResQ products used in animal critical care and veterinary applications.
Regulatory, clinical, and commercialization support tied to product adoption and market expansion.
Asiakkaat
The company sells primarily to hospitals, intensive care units, and cardiac surgery teams that use its devices in acute, high-risk procedures. It also targets physicians, healthcare systems, and payers that must be convinced of clinical benefit, reimbursement value, and regulatory acceptance before broad adoption occurs.
Buy CytoSorb for ICU patients with sepsis, septic shock, respiratory failure, and other acute inflammatory conditions.
Use CytoSorb or DrugSorb-ATR-related therapies to manage bleeding and drug-removal needs around surgery.
Influence purchasing by adopting the therapy, generating clinical evidence, and driving protocol inclusion.
Assess whether the therapy is reimbursed and economically justified, affecting adoption speed.
Buy VetResQ for animal critical care use, a smaller but strategically relevant niche.
Strategia
Management is focused on expanding commercial adoption while advancing regulatory approvals for DrugSorb-ATR in the U.S. and Canada. At the same time, the company is cutting costs, reducing headcount, and trying to reach cash-flow breakeven to reduce financing pressure and support continued development.
Approval would unlock a large new market and materially improve commercialization prospects.
Lower spending is needed to preserve liquidity and reach cash-flow breakeven.
Broader physician acceptance and guideline inclusion are needed for sustained sales growth.
The company already has regulatory access in Europe and many other countries, which remains its main revenue base.
Maantiede
Q1/2026CytoSorbents is headquartered in Princeton, New Jersey, but its commercial footprint is international, with CytoSorb distributed in more than 70 countries. The company’s core commercial base is outside the U.S., especially in Europe, while U.S. and Canadian growth depends on regulatory approvals that are still pending for key products such as DrugSorb-ATR.
Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.
Riskit
The company is highly exposed to regulatory outcomes, especially for DrugSorb-ATR in the U.S. and Canada, where approval delays or denials could materially limit growth. It also faces adoption risk because hospitals, physicians, and payers may not accept the therapy without stronger clinical evidence, reimbursement support, and market education. Liquidity and going-concern pressure add financing risk, while competition and Nasdaq listing compliance remain additional business risks.
- Regulatory failure for DrugSorb-ATRVaikutus: KorkeaTodennäköisyys: Korkea
The product candidate needs FDA and Health Canada authorization before meaningful North American sales can begin.
Kohdistuu: U.S. and Canada growth
- Market acceptance riskVaikutus: KorkeaTodennäköisyys: Korkea
Hospitals and clinicians may not adopt the devices without sufficient evidence, reimbursement, and guideline support.
Kohdistuu: CytoSorb and new product launches
- Financing and going-concern riskVaikutus: KorkeaTodennäköisyys: Korkea
Cash resources and operating losses create dependence on external funding and cost reductions.
Kohdistuu: Corporate liquidity
- Nasdaq listing complianceVaikutus: KeskitasoTodennäköisyys: Korkea
Failure to meet listing standards could hurt stock liquidity and investor access to capital.
Kohdistuu: Public equity market access
- Competitive and reimbursement pressureVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Competing technologies or unfavorable payer policies could reduce adoption and pricing power.
Kohdistuu: Global commercial markets
Kirjanpito
Harkinnanvaraiset erätDevice sales across geographies and product launches can create timing differences in reported revenue.
Vaikutus: Affects quarterly comparability and growth rates
Management disclosed substantial doubt about continuing as a going concern without additional capital.
Vaikutus: Signals financing dependence and potential dilution
The workforce and cost reduction plan will create severance and related charges.
Vaikutus: Impacts operating expenses and short-term earnings
Equity awards can materially affect SG&A and reported losses.
Vaikutus: Non-cash expense affects profitability trends
Royalty arrangements can change with contract expirations and product sales mix.
Vaikutus: Affects gross margin and operating leverage
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
CytomX Therapeutics, Inc.
CTMX · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment.
CytoDyn Inc.
CYDY · Pharmaceutical Preparations
Cytokinetics, Incorporated
CYTK · Pharmaceutical Preparations
Cytokinetics is a U.S.-based specialty biopharmaceutical company built around muscle biology and the mechanics of contractility.
Sigyn Therapeutics, Inc.
SIGY · Surgical & Medical Instruments & Apparatus
Aethlon Medical, Inc
AEMD · Surgical & Medical Instruments & Apparatus
aTyr Pharma, Inc
ATYR · Biological Products, (No Diagnostic Substances)
aTyr Pharma is a U.S.-based biotechnology company focused on discovering and developing protein-based therapeutics derived from tRNA synthetase biology.
Päivitetty: 24.9.2026